Lupin plays down impact of Mylan’s generic version of anti-cholesterol drug
With US generics drugmaker Mylan starting the shipment of a generic version of Lupin's anti-cholesterol drug Antara, the revenue impact may be significant for Lupin. S Ramesh, president of finance and planning, Lupin, told NDV Profit that the impact will be nullified by the two other branded products that Lupin has in the US, especially after the US drug regulator’s nod for its Suprax drug.
